Antibodies against the ectodomain of ERBB3 and uses thereof
US9487588B2 · kind B2 · utility
3Cited by
21References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 14, 2014 |
| Grant date | Nov 8, 2016 |
| Priority date | — |
| Expiry date | Feb 14, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a novel class of antibodies and antigen binding fragments thereof that bind the extracellular domain of ErbB3 receptor and inhibit various ErbB3 functions. For example, the antibodies and antigen binding fragments described herein are capable of binding to the receptor designated ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor. Such antibodies and antigen binding fragments thereof have the useful characteristic of inhibiting the proliferation of cancer cells expressing ErbB3.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.